超凡蜘蛛侠
Director Wen Muye speaks on latest anti-war movie_我的网站
一 |
It centers on an ordinary Chinese chef caught in the crossfire of war. Shen Teng stars as Xu Fu, a cook who travels to the fictional Middle Eastern capital of Bahata to repay family debts. There he joins forces with restaurant manager Ma Junsheng (actor Jiang Qiming) to run a Chinese eatery. When conflict erupts, the self-preserving every-man endures personal losses and gradually comes to protect local children.
Produced by Ning Hao, the film continues Wen's signature focus on "little people," this time placing them far beyond China's borders.
In an interview with the Global Times, Wen talked about the project's connection to news reports of Chinese migrants who open restaurants overseas and forge quiet connections through food.
"Many Chinese people go abroad simply to make a living," he told the Global Times. "They open restaurants, use food to break down regional barriers, and form deep bonds with locals."
The production team conducted extensive research and location scouting in the Middle East to capture everyday details. Elements such as free-running single-humped camels required overseas shoots; the resulting images of open space after confinement, Wen noted, carry a simple sense of hope.
Food functions as the film's central motif.
"Food more often stands for happiness and peace," Wen explained. "Even in a war-torn environment, people still cannot do without three meals a day. That sounds basic, but after all the big things in life, what people care about most are the simplest things - eating a proper meal and taking care of family."
A specialized food unit developed the dishes, and Shen trained extensively so that most of the wok-tossing sequences were performed by the actor himself, Wen said.
The film deliberately intercuts kitchen routines with combat sequences.
"Three meals a day represent our longing for peaceful life, while war is the extreme act that destroys peaceful life on a large scale," Wen said. "When they collide, each becomes clearer: Food feels more ordered and full of happiness; war feels more chaotic and dark."
He hopes the juxtaposition helps audiences recognize how hard-won ordinary peace really is.
Xu Fu's decision to shelter orphans never relies on lofty rhetoric, only a meal and a roof. Wen described this approach as rooted in a human-centered outlook rather than classic Western hero narratives.
"We place more weight on humanism and the value of a person's existence. Our culture is about living well, studying well, eating well, and looking after children. No matter how large the events, three meals a day remain unavoidable. Food itself has warmth and can give people real strength when they are in a difficult situation," Wen said.
The director noted that he wants viewers to leave with the plainest conviction: live properly, eat properly, and cherish the peace that exists in the present.
On balancing personal expression with commercial reach, Wen kept his principle simple: "Make the film well and tell the story well. I try to put what I want to express into foreshadowing and details without hurting the viewing experience. If audiences notice those details, I will be glad. If they do not, it does not affect the normal narrative."
From Dying to Survive and Miracle: Stupid Kid to the new film, Wen's view of human complexity has remained consistent. "People have many different sides. They face different circumstances and make different choices."
The through-line, he added, is the same plain belief: "Being able to enjoy a proper meal is the greatest happiness."
Early audience response has been overwhelmingly positive. Advanced screenings delivered scores of 9.7-9.8 on major Chinese platforms including ticketing platform Maoyan.
Many entered expecting a light Shen Teng comedy and left in tears, describing the experience as "laughing then crying." Shen's restrained performance has drawn particular praise, with some calling it the strongest of his career. Jiang's supporting work has also been widely noted.
Moviegoers have frequently highlighted the film's refusal to deliver speeches. Its focus on daily meals and small acts of care lands more powerfully than any slogan.
On the depiction of the conflict, audiences observe that the movie offers a perspective that "flips the Hollywood script" by casting the US as the invader, while refusing to portray US soldiers as pure villains. Instead they appear as ordinary young men: loose in discipline and marked by the alienation of war.
Both Chinese and overseas viewers have singled out this measured approach as part of the film's distinctive Chinese viewpoint: It sidesteps both Western hero narratives and simple demonization. Some international comments note that by staying with ordinary lives rather than choosing geopolitical sides, the story offers a different lens on conflict.
One widely circulated comment from a popular Chinese self-media account on WeChat captured the film's ambition: "You can think of this film as a blend of Casablanca, Schindler's List, and The Shawshank Redemption, yet at its core lies the same grounded human compassion found in Dying to Survive. This is a highly successful attempt by Chinese filmmakers to surpass Hollywood. It is the first Chinese film that truly possesses a global vision and a professional sense of international storytelling. It is also a gift of warmth and goodwill from the Chinese people to a world still torn by war and cruelty."
。
二 | 继美国药企莫德纳宣布癌症疫苗取得积极进展后，其高昂的价格也引发了关注，“癌症疫苗近50万美元一针”等相关话题登上热搜。
近日，莫德纳与疫苗巨头默沙东宣布，两家公司联合研发个性化mRNA癌症疫苗Intismeran Autogene（研发代号mRNA-4157/V940）联合PD-1抑制剂帕博利珠单抗（俗称“K药”）治疗黑色素瘤的Ⅲ期临床试验取得积极结果，无复发生存期和无远处转移生存期均达到关键终点。 该消息一出，莫德纳股价当日飙涨177%，至174.38美元，创下多年以来新高。
三 | 在引发资本市场狂热的同时，“癌症疫苗”昂贵的价格也令人咂舌，被认为是富人的游戏。 据中国新闻周刊援引美国投资银行William Blair估算的数据，这款药的批发采购成本大约要47.5万美元，约合人民币318万元。上海市公共卫生临床中心血液肿瘤科主任医师詹其林在接受媒体采访时也曾表示，目前，该款药物估计单人生产成本超过10万美元，从取样到打上第一针约需6至9周。 该款药物成本昂贵，与其研发周期长、投入资金大等因素有关。据中国新闻周刊介绍，一款创新药从启动研发到上市，平均投入超10亿美元，研发周期超过10年。莫德纳财报显示，2025年其营收约19亿美元，全年亏损28亿美元，其中研发费用消耗了约31亿美元。
四 | mRNA癌症疫苗需要“个性化定制”也在一定程度上提高了成本。作为全球首款进入上市冲刺阶段的个体化新抗原mRNA癌症疫苗，Intismeran采用“一人一药、量身定制”，每位患者需要经历手术取样、测序、分析突变、设计合成mRNA、再用脂质纳米颗粒包装、质检放行等多个环节。此外，intismeran还不是单独用药，其临床试验是联合默沙东的K药一同进行。 需要注意的是，治疗性癌症疫苗并非用于健康人的预防，而是针对已确诊癌症患者的个性化免疫疗法。以intismeran为例，它是高危黑色素瘤术后辅助治疗手段，仅用于已经做完手术的高危黑色素瘤患者，目标是降低术后复发风险。
五 | 黑色素瘤，全称为恶性黑色素瘤，是起源于皮肤中黑色素细胞的高度恶性肿瘤，被称为“皮肤癌之王”。黑色素瘤虽仅占皮肤癌约1%，却是皮肤癌死亡的主要诱因，术后2至3年为复发高发期。
六 | 根据世界癌症研究基金会2020年的数据，全球每年有超过15万人患黑色素瘤。在我国黑色素瘤比较少见，整体粗发病率0.62/10万，标化发病率仅为0.37/10万，2022年全国新发病例8789例。黑色素瘤患者数量较少，也在某种程度上对摊薄研发成本带来了挑战。 此次mRNA技术在三期试验中获得成功，让业界看到了更多可能和希望。
七 | 有分析认为，这意味着该技术开始从概念验证迈向注册申报和商业化。如果后续获得监管批准，它将成为全球首个上市的mRNA肿瘤疫苗，开启个体化肿瘤疫苗治疗的新时代。 不过，从首个适应证获批到真正广泛应用，还要解决肿瘤测序、个体化设计、单人单批生产、质量放行、治疗周期、定价和医保支付等问题。因此，它可能较快实现有限范围上市，但形成规模化临床应用仍需3-5年。 谈及该技术大规模商业化面临的挑战，mRNA领域专家、mRNA创新药物研发商惠正奇医药创始人回爱民在接受蓝鲸新闻采访时表示，仍有几方面难题需要突破，包括新抗原筛选的准确性、不同癌种存在差异、个体化生产和质量控制、监管问题，以及成本和可及性。 据了解，国内目前还没有mRNA肿瘤治疗疫苗完成人体商业化获批，在抗原筛选、完整闭环能力上仍与国外企业存在差距。有分析认为，mRNA癌症疫苗赛道的原始创新风险较高，等待海外头部企业完成路径验证后，国内企业可以再集中资源投入，重点做工艺优化、降本增效、本土化改造，走出类似国内CAR-T产业的发展轨迹。
（文章来源：界面新闻）。
Current article:http://jkcbsd.gamajionghuanmuniuzhuanguchu.cyou/57ug/20260826/5444771.html
Published on:17:31:20